By: Manika Premsingh
Bristol-Myers Squibb's earnings surprise in Q3 2024, approvals for its schizophrenia treatment and Opdivo's for lung cancer along with a positive outlook for 2025 bode well for the stock.
Manika Premsingh is an exclusive articles writer for Seeking Alpha, with her work also appearing in Yahoo Sports UK. She specializes in providing analysis and insights on various stocks and investment opportunities, focusing on dividend growth, price trends, and market indicators. Her articles aim to provide valuable information for investors looking to make informed decisions in the financial market.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Manika Premsingh's articles primarily focus on investment analysis and cite data extensively. Her coverage centers around stocks, earnings, dividends, and rating upgrades/downgrades.
To effectively reach out to Manika, consider offering fact-based insights and analyses related to stock performance, earnings reports, dividend trends or potential rating changes. Given her emphasis on citing data in her articles, providing well-supported arguments with robust statistics could enhance the chances of successful outreach.
Manika does not appear to have a specific geographic focus but rather provides analyses from an international perspective. Therefore, pitches focusing on global market trends or specific companies with worldwide significance may be well received by her.
This information evolves through artificial intelligence and human feedback. Improve this profile .